Get Started

Universe Pharmaceuticals INC Announces Strategic Acquisition to Expand Pharmaceutical Patent Portfolio

GlobeNewswire· June 26, 2026

Universe Pharmaceuticals INC has entered into a share purchase agreement to acquire 100% of Best Praise International Limited for approximately $10.75 million. The deal, which is payable in Class A ordinary shares, secures a portfolio of five Chinese patents focused on age-related diseases, neurodegenerative conditions, and drug delivery technologies. This move is significant for the pharmaceutical sector as it signals a strategic shift for the China-based company to broaden its intellectual property and R&D capabilities beyond traditional Chinese medicine derivatives.

Universe Pharmaceuticals INC (NASDAQ: UPC), a Ji'an-based producer and distributor, has agreed to acquire Best Praise International Limited for a total purchase price of US$10,751,000. The transaction will be settled through the issuance of 4,376,552 Class A ordinary shares of the Company. Through this acquisition, Universe Pharmaceuticals gains control over five patents registered in China that have potential applications in pharmaceutical development. The transaction has received board approval and is expected to close in the third quarter of 2026, subject to customary closing conditions.

The acquired patent portfolio covers a diverse range of high-value therapeutic areas, including cardiovascular-related applications, cognitive disorders, and neurodegenerative conditions. Additionally, the intellectual property includes antibacterial compounds and advanced drug delivery technologies. These assets are intended to complement the company's existing focus on elderly healthcare and traditional Chinese medicine (TCM) derivatives. CEO Gang Lai noted that the acquisition is designed to broaden the company's product pipeline and provide new avenues for research and development, licensing arrangements, and co-development efforts.

For the pharmaceutical industry, this acquisition represents an effort by a specialized TCM producer to strengthen its asset base and enhance its profile as a Nasdaq-listed entity. By integrating these patents, Universe Pharmaceuticals aims to transition into more complex pharmaceutical applications and improve its long-term capital position. The company currently operates a distribution network spanning 30 provinces in China, selling both its own TCM products and third-party biomedical drugs and medical instruments. This strategic expansion into proprietary intellectual property is expected to create long-term value for shareholders by addressing the physical conditions associated with the aging process.

Read the full story at GlobeNewswire

Summary generated by RabbitReport AI from public reporting. The full article and original reporting belong to GlobeNewswire.

More in Pharmaceutical

FDA Chooses 7 Companies for PreCheck Pilot

The U.S. Food and Drug Administration has announced the selection of seven companies to participate in its new PreCheck pilot program. This initiative aims to explore more efficient regulatory pathways and oversight mechanisms for the pharmaceutical industry. The program's outcomes could influence future compliance standards and the speed of regulatory approvals for participating manufacturers. By collaborating with these selected firms, the FDA intends to modernize its approach to industry oversight and supply chain integrity.

June 30, 2026

GAO Report Finds Federal Research Fuels Pharmaceutical Profits with Minimal Taxpayer Return

A new Government Accountability Office (GAO) report released in June 2026 investigates how federal research funding translates into private pharmaceutical profits. The report highlights the role of agencies like the National Institutes of Health (NIH) in bearing the financial risk of early-stage discovery before private companies license the findings for commercial development. This examination is critical for the pharmaceutical sector as it addresses the growing tension between public investment in innovation and the high cost of resulting medications for U.S. patients.

June 30, 2026

Seven Companies Selected for FDA Pilot to Strengthen US Drug Supply Chain

The U.S. Food and Drug Administration has selected seven companies to participate in a new pilot program focused on strengthening the domestic pharmaceutical supply chain. This initiative aims to enhance the security and resilience of drug distribution networks to prevent critical medicine shortages. For the pharmaceutical sector, this program represents a significant effort to modernize logistics and ensure the continuous availability of essential treatments for patients. By collaborating with industry partners, the FDA seeks to identify best practices that can be scaled to protect the integrity of the entire U.S. drug market.

June 30, 2026

Lilly and Regeneron amongst first incumbents to FDA’s fast-track facility scheme

Eli Lilly and Regeneron have been identified as early participants in the FDA’s new fast-track facility scheme. This program is designed to expedite the regulatory review and approval process for pharmaceutical manufacturing sites. By streamlining these inspections, the initiative aims to facilitate faster market entry for critical medications and improve supply chain efficiency. The involvement of these major incumbents underscores the pharmaceutical industry's move toward modernized regulatory frameworks for production infrastructure.

June 30, 2026